Mitchell I Kennedy1, Kaitlyn Whitney1, Thos Evans2, Robert F LaPrade3,4. 1. Steadman Philippon Research Institute, 181 West Meadow Drive, Suite 400, Vail, CO, 81657, USA. 2. The Steadman Clinic, Vail, CO, USA. 3. Steadman Philippon Research Institute, 181 West Meadow Drive, Suite 400, Vail, CO, 81657, USA. rlaprade@thesteadmanclinic.com. 4. The Steadman Clinic, Vail, CO, USA. rlaprade@thesteadmanclinic.com.
Abstract
PURPOSE OF REVIEW: To assess the utilization and efficacy of platelet-rich plasma (PRP), for the treatment of articular cartilage injury, most commonly characterized by progressive pain and loss of joint function in the setting of osteoarthritis (OA). RECENT FINDINGS: PRP modulates the inflammatory and catabolic environment through a locally applied concentrate of platelets, leukocytes, and growth factors. Clinically, PRP has been shown to be possibly a viable treatment adjuvant for a variety of inflammatory and degenerative conditions. Recent efforts have focused on optimizing delivery methods that enable platelets to slowly degranulate their biological constituents, which may promote healing and improve OA symptoms for a longer duration. There are various factors that affect the progression of OA within joints, including inhibition of inflammatory cytokines and altering the level of enzymatic expression. PRP therapy aims to mediate inflammatory and catabolic factors in a degenerative environment through the secretion of anti-inflammatory factors and chemotaxic effects. There are a growing number of studies that have demonstrated the clinical benefit of PRP for non-operative management of OA. Additional randomized controlled trials with long-term follow-up are needed in order to validate PRP's therapeutic efficacy in this setting. Additionally, continued basic research along with well-designed pre-clinical studies and reporting standards are necessary in order to clarify the effectiveness of PRP for cartilage repair and regeneration for future clinical applications.
PURPOSE OF REVIEW: To assess the utilization and efficacy of platelet-rich plasma (PRP), for the treatment of articular cartilage injury, most commonly characterized by progressive pain and loss of joint function in the setting of osteoarthritis (OA). RECENT FINDINGS: PRP modulates the inflammatory and catabolic environment through a locally applied concentrate of platelets, leukocytes, and growth factors. Clinically, PRP has been shown to be possibly a viable treatment adjuvant for a variety of inflammatory and degenerative conditions. Recent efforts have focused on optimizing delivery methods that enable platelets to slowly degranulate their biological constituents, which may promote healing and improve OA symptoms for a longer duration. There are various factors that affect the progression of OA within joints, including inhibition of inflammatory cytokines and altering the level of enzymatic expression. PRP therapy aims to mediate inflammatory and catabolic factors in a degenerative environment through the secretion of anti-inflammatory factors and chemotaxic effects. There are a growing number of studies that have demonstrated the clinical benefit of PRP for non-operative management of OA. Additional randomized controlled trials with long-term follow-up are needed in order to validate PRP's therapeutic efficacy in this setting. Additionally, continued basic research along with well-designed pre-clinical studies and reporting standards are necessary in order to clarify the effectiveness of PRP for cartilage repair and regeneration for future clinical applications.
Authors: Soumen Basak; Hana Kim; Jeffrey D Kearns; Vinay Tergaonkar; Ellen O'Dea; Shannon L Werner; Chris A Benedict; Carl F Ware; Gourisankar Ghosh; Inder M Verma; Alexander Hoffmann Journal: Cell Date: 2007-01-26 Impact factor: 41.582
Authors: Marjan M C Steenvoorden; Tom W J Huizinga; Nicole Verzijl; Ruud A Bank; H Karel Ronday; Hilco A F Luning; Floris P J G Lafeber; René E M Toes; Jeroen DeGroot Journal: Arthritis Rheum Date: 2006-01
Authors: Peter Cornelius Kreuz; Jan Philipp Krüger; Sebastian Metzlaff; Undine Freymann; Michaela Endres; Axel Pruss; Wolf Petersen; Christian Kaps Journal: Arthroscopy Date: 2015-05-13 Impact factor: 4.772
Authors: Marta Torres-Torrillas; Elena Damiá; José J Cerón; José M Carrillo; Pau Peláez; Laura Miguel; Ayla Del Romero; Mónica Rubio; Joaquín J Sopena Journal: Cartilage Date: 2021-12-03 Impact factor: 3.117
Authors: Dorottya Kardos; Bence Marschall; Melinda Simon; István Hornyák; Adél Hinsenkamp; Olga Kuten; Zsuzsanna Gyevnár; Gábor Erdélyi; Tamás Bárdos; Tamás Mirkó Paukovits; Krisztián Magos; György Béres; Kálmán Szenthe; Ferenc Bánáti; Susan Szathmary; Stefan Nehrer; Zsombor Lacza Journal: Cells Date: 2019-08-03 Impact factor: 6.600